As IL-6 inhibition comes into practice for PMR, research advances on other therapeutic mechanisms of action, from IL-17 to ...

Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable ...

Patients with RA who use abatacept mount little humoral or cell-mediated responses to the recombinant zoster vaccine, with more injection-site reactions but similar RA flare rates compared with ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Setmelanotide receives FDA approval for acquired hypothalamic obesity based on phase 3 trial data demonstrating meaningful body mass index reductions.

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient ...

Please provide your email address to receive an email when new articles are posted on . Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to ...

T he recent reimbursement of Bimzelx (bimekizumab) in Ireland represents an important step forward in access to treatment for people living with immune-mediated diseases, includin ...